Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, has recently signed an investment agreement with Chordia Therapeutics Inc. (Head office: Fujisawa City, Kanagawa Prefecture; Representative Director: Hiroshi Miyake), a venture company utilizing research results from Kyoto University.

Investment Agreement with Chordia
Chorida is a venture company founded by six researchers, led by Mr. Miyake, a former oncology drug discovery research leader at Takeda Pharmaceutical Company Limited, and its core business is the research and development of novel anticancer drugs.

Miyake and his research group have long collaborated with Professor Seiji Ogawa (Department of Tumor Biology, Kyoto University Graduate School of Medicine) on several research programs based on Professor Ogawa's world-class research results in the field of cancer genomics. Chordia will now take over the collaborative research with Prof. Ogawa.

Kyoto iCAP highly evaluated Chordia's management philosophy of bringing novel therapeutic drugs to patients suffering from refractory cancers and the potential of Chordia's pipeline, and decided to underwrite a portion of the private placement of new shares to be conducted by the company. Takeda, SMBC Venture Capital, and Mitsubishi UFJ Capital will also participate in this private placement.

Details of this investment will be disclosed in a press release and other media in the near future.

Chordia Therapeutics Corporation Overview

Establishment	October 12, 2017
Business	Research and development of novel anticancer drugs
Head Office Location	Fujisawa City, Kanagawa Prefecture
President & CEO	Hiroshi Miyake